{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:17:54Z","timestamp":1780381074378,"version":"3.54.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"DOI":"10.7759\/cureus.79548","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:59:14Z","timestamp":1740394754000},"source":"Crossref","is-referenced-by-count":2,"title":["Chronic Eosinophilic Leukemia Positive for FIP1L1-PDGFRa"],"prefix":"10.7759","author":[{"given":"Steven J","family":"Haydon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Caucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borys","family":"Hrinczenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Bone marrow neoplastic. chronic eosinophilic leukemia. (2023). Accessed: February 19th, 2025: https:\/\/www.pathologyoutlines.com\/topic\/myeloproliferativeCEL.html."},{"key":"ref2","article-title":"Eosinophilic syndromes","author":"Klion AD","year":"2020","unstructured":"Klion AD . Eosinophilic syndromes. Goldman-Cecil medicine.  Goldman L, Schafer AI (ed): Elsevier, 2020. 156:1162-5."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.03.035","article-title":"Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence","volume":"126","author":"Crane MM","year":"2010","unstructured":"Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol. 2010, 126:179-81. 10.1016\/j.jaci.2010.03.035","journal-title":"J Allergy Clin Immunol"},{"key":"ref4","unstructured":"Chronic eosinophilic leukemia (CEL). Accessed. February 19th, 2025: https:\/\/seer.cancer.gov\/seertools\/hemelymph\/51f6cf58e3e27c3994bd53fc\/.."},{"key":"ref5","unstructured":"Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes. (2025). Accessed. February 20, 2025: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1505."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12955","article-title":"How I investigate eosinophilia","volume":"41","author":"Larsen RL","year":"2019","unstructured":"Larsen RL, Savage NM. How I investigate eosinophilia. Int J Lab Hematol. 2019, 41:153-61. 10.1111\/ijlh.12955","journal-title":"Int J Lab Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib J","year":"2008","unstructured":"Gotlib J, Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia. 2008, 22:1999-2010. 10.1038\/leu.2008.287","journal-title":"Leukemia"},{"key":"ref8","article-title":"Mastocytosis","author":"Akin C","year":"2020","unstructured":"Akin C. Mastocytosis. Goldman-Cecil medicine. Goldman L, Schafer AI (ed): Elsevier, 2020. 235:1699-1704."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib J","year":"2017","unstructured":"Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017, 92:1243-59. 10.1002\/ajh.24880","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2007.060196","article-title":"A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint","volume":"9","author":"Lambert F","year":"2007","unstructured":"Lambert F, Heimann P, Herens C, Chariot A, Bours V. A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint. J Mol Diagn. 2007, 9:414-9. 10.2353\/jmoldx.2007.060196","journal-title":"J Mol Diagn"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2007.06.001","article-title":"Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome","volume":"27","author":"Bain BJ","year":"2007","unstructured":"Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2007, 27:377-88. 10.1016\/j.iac.2007.06.001","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPMORR5Z2IKCEM","article-title":"Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1","volume":"144","author":"Vega F","year":"2015","unstructured":"Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. Am J Clin Pathol. 2015, 144:377-92. 10.1309\/AJCPMORR5Z2IKCEM","journal-title":"Am J Clin Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-286757","article-title":"Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease","volume":"117","author":"Elling C","year":"2011","unstructured":"Elling C, Erben P, Walz C, et al.. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood. 2011, 117:2935-43. 10.1182\/blood-2010-05-286757","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion AD","year":"2007","unstructured":"Klion AD, Robyn J, Maric I, et al.. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood. 2007, 110:3552-6. 10.1182\/blood-2007-07-100164","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah NP","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, et al.. Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology . J Natl Compr Canc Netw. 2024, 22:43-69. 10.6004\/jnccn.2024.0007","journal-title":"J Natl Compr Canc Netw"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani A","year":"2016","unstructured":"Pardanani A, Lasho T, Wassie E, et al.. Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia. 2016, 30:1924-6. 10.1038\/leu.2016.73","journal-title":"Leukemia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/337431-chronic-eosinophilic-leukemia-positive-for-fip1l1-pdgfra","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:59:16Z","timestamp":1740394756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/337431-chronic-eosinophilic-leukemia-positive-for-fip1l1-pdgfra"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.79548","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}